Slides
Page 1
BLENDING STRENGTH. BUILDING THE HIVE. Camlin Fine Sciences Limited Investor Presentation – November 2026
Page 2
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Camlin Fine Sciences Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company. 2
Page 3
Q2 & H1FY27 Financial Highlights
Page 4
4*EBITDA is adjusted for FX loss Revenue (Rs. In Mn) Operational EBITDA* (Rs. In Mn) PAT (Rs. In Mn) 356 176 22 559 199 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 7.91% 3.39% 0.45% 6.52% 1.97% Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 EBITDA Margin % -19 -318 -281 -50 -599 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 Q2 & H1FY27 Financial Highlights On Consolidated Basis 4,503 5,199 4,915 8,580 10,113 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 On Continued Operations
Page 5
5 Key Operational Highlights Outlook — FY27 • Blends: Growth momentum to continue across all geographies. Vitafor and Vinpai to stabilise. • Aroma: Anticipate an improvement in volumes and realisations over the coming quarters. • External Challenges: Ongoing logistics disruptions and inflationary pressures are expected to weigh on operations in the near term. • Board has approved the fundraise through rights issue to address liquidity challenges upto Rs 2,500 mn Financial Performance • Revenue came in at Rs 4,915 mn, up 9.15% YoY. • Gross margin came in at 39.8% (46.5% in Q2 FY26) due to higher RM prices, limited pass-through, and liquidity issues which further impacted the EBITDA. • Incurred Rs. 51 mn in maintenance expenses at the Diphenol Dahej unit, despite the facility remaining non- operational. • EBITDA for the quarter stood at Rs 22.3 mn; margin 0.45%. Strategic Acquisition • Acquired additional 11% stake from the minority shareholder of Vinpai at Rs 201 mn leading to total holding at 94.82%. Operating Environment • Elevated raw material prices continue to impact the profitability of the company. • Higher operating costs driven by increased freight expenses, extended transit times and longer working capital cycles. Segmental Highlights • Straights: Revenue grew by 26% on YoY basis to Rs 1,108 mn due to healthy volume growth despite local competition • Blends continues its robust growth revenue grew by 25% on YoY basis • Aroma: Revenue declined 41% YoY due to changeover to Methyl Vanillin during the quarter leading to lower utilization and higher unabsorbed costs *EBITDA is adjusted for FX lossOn Consolidated Basis
Page 6
6 Segmental Highlights – Q2 & H1FY27 Specialty Ingredients STRAIGHTS ₹1,108 Revenue BLENDS ₹2,970 Revenue Aroma ₹472 Revenue (23.1)% EBITDA Performance Chemicals & Others ₹1,857 Revenue (10.6)% EBITDA Key Focus To Improve Margins Working Capital Cycle New products in functional ingredients STRAIGHTS ₹2,036 Revenue BLENDS ₹6,056 Revenue 7.20% EBITDA ₹1,246 Revenue (11.5)% EBITDA ₹3,606 Revenue (6.7)% EBITDA ▪ Attractive growth markets across geographies ▪ Extensive product range – Clean label products ▪ New technologies & Functional Ingredients ▪ Margins to improve with enhanced utilization ▪ Methyl Vanillin Campaign in mid August ▪ High costs impacting the vertical ▪ Diphenol plant is under shutdown ▪ Includes Intersegment transaction 8.04% EBITDA Q2 FY27 Highlights H1 FY27 Highlights Key Highlights
Page 7
Specialty Ingredients (Rs. In Mn) (Straights) Specialty Ingredients (Rs. In Mn) (Value added blends) Total Specialty Ingredients (Rs. In Mn) On Consolidated Basis Performance Chemicals & Others (Rs. In Mn) Aroma Ingredients (Rs. In Mn) 7 882 927 1,108 1,696 2,036 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 +26% +20% 2,349 3,086 2,970 4,471 6,056 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 +26% +35% 3,231 4,013 4,079 6,167 8,092 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 +26% +31% 1,572 1,749 1,857 3,084 3,606 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 +18% +17% 799 774 472 1,365 1,246 Q2 FY26 Q1 FY27 Q2 FY27 H1 FY26 H1 FY27 -41% -9% Operational Revenue Breakup Performance Chemicals revenue includes intersegment revenue 359 Adjusted EBITDA 255 328 659 583 -90 -44 -197 -166 -241 1,100 1,337 1,492 2,037 2,830 87 -34 -109 67 -142
Page 8
Particulars (Rs. In Mn) Q2 FY27 Q2 FY26 Q1 FY27 H1 FY27 H1 FY26 Revenue from Operation 4,914.7 4,502.6 5,198.8 10,113.4 8,579.9 Raw material consumption 2,956.9 2,411.1 3,056.8 6,013.7 4,667.9 Employee Cost 722.7 594.7 734.3 1,457.0 1,162.1 Other expenses 1,212.8 1,140.6 1,314.9 2,491.7 2,190.6 EBITDA 22.3 356.3 92.7 151.0 559.2 EBITDA Margins (%) 0.45% 7.91% 1.78% 1.49% 6.52% Adjusted EBITDA* 22.3 356.3 176.4 198.8 559.2 Adjusted EBITDA Margins (%) 0.45% 7.91% 3.39% 1.97% 6.52% Other Income 49.6 42.6 13.4 27.0 108.9 Depreciation 199.2 176.5 191.6 390.8 337.9 Finance cost 205.9 178.5 140.1 346.0 327.0 Exceptional Item 19.3 - 111.1 130.4 - Share of profit / (loss) of associate 3.6 (3.6) 14.0 17.6 5.3 PBT (348.9) 40.3 (322.6) (671.5) 8.5 Tax (68.1) 59.0 (4.6) (72.7) 58.7 PAT (280.8) (18.7) (318.0) (598.8) (50.2) 8*EBITDA is adjusted for FX loss PBT from discontinued operation (16.2) (130.8) (18.3) (34.4) (205.8) Tax expense of discontinued operations 0.0 0.0 0.0 0.0 0.3 PAT including Discontinued Operations (297.0) (149.5) (336.2) (633.2) (256.3) From Discontinued Operations# From Continuing Operations # Pertains to CFS Europe and CFSWL discontinued operations Consolidated Profit & Loss Statement
Page 9
9 Particulars (Rs. In Mn) Sept – 26 Mar – 26 Equity Equity Share Capital 192.1 192.1 Other Equity 9,528.6 10,216.7 Minority interest (407.2) (400.7) Total Equity 9,313.6 10,008.1 Non-Current Liabilities Financial Liabilities Borrowings 2,653.6 3,026.1 Lease Liabilities 418.7 344.0 Other Liabilities 3.8 3.2 Provisions 75.0 72.8 Deferred Tax Liabilities (Net) 39.1 39.1 Other non-current liabilities 1.5 1.6 Total Non-Current Liabilities 3,191.6 3,486.7 Current Liabilities Financial Liabilities Borrowings 3,640.0 3,654.7 Lease Liabilities 169.5 176.1 Trade Payables 5,460.8 5,051.9 Other Financial Liabilities 592.1 617.8 Other Current Liabilities 222.1 151.9 Provisions 85.7 91.0 Current tax liabilities (Net) 1.1 0.8 Total Current Liabilities 10,171.5 9,744.2 Total Equity and Liabilities 22,676.6 23,239.1 Particulars (Rs. In Mn) Sept – 26 Mar – 26 Non-Current assets Property, Plant and Equipment 5,711.2 5,692.1 Capital Work-In-Progress 237.0 328.5 Right use of assets 615.6 558.8 Goodwill 2,334.1 2,334.1 Other Intangible Assets 265.2 288.7 Intangible assets under development 0.0 0.0 Investment Property 0.0 0.0 Financial Assets Investments 310.1 302.6 Other Financial Assets 187.8 183.5 Deferred tax assets 1,001.6 873.8 Income Tax Assets 188.9 251.6 Other Non-Current Assets 49.9 60.2 Total Non-Current Assets 10,901.4 10,874.1 Current Assets Inventories 5,805.4 5,037.4 Financial Assets Investments 0.0 0.0 Trade Receivables 3,371.7 3,730.2 Cash and Cash Equivalents 495.0 1,085.6 Bank Balances 191.8 446.7 Loans 0.0 0.0 Other Financial Assets 340.7 578.3 Other Current Assets 1,549.2 1,465.2 Assets held for sale 21.6 21.6 Total Current Assets 11,775.3 12,343.3 Total Assets 22,676.6 23,239.1 Consolidated Balance Sheet
Page 10
Company Overview
Page 11
11# Excludes CFS Europe and CFSWL discontinued operations Food & Beverage Animal Nutrition Pet Food Pharmaceuticals & Pharma Intermediates Petrochemicals Dyes & Pigments Poultry & Livestock Bio-Fuels Aquaculture & Fishmeal Flavours & Fragrances Dietary Supplements Personal Care & Home Care Polymers Agrochemicals Incense Sticks Catering Diverse Industries Global specialty ingredients company providing Shelf-life, Aroma and Performance solutions 100+ Range of Diversified Products Offering Wide Range of Blends & Vanillin Preferred Partner For Customized Shelf-Life Solutions Among Global Leaders In the Manufacturing of Antioxidants 8 Global Manufacturing Facilities 7 Application Laboratories 2 R&D Centres 80+ Countries 1,300+ Customers Worldwide FY26 Revenue Mix*# ₹ 17,233 mn 14% 10% 58% 18% Specialty Ingredients Value added Blends Performance Chemicals Aroma Ingredients Company Overview
Page 12
12 # From continued operations India | Brazil | Mexico | France | Belgium Manufacturing Backbone Scale. Reliability. Consistency. Core production hubs anchor the network, ensuring uninterrupted supply and quality. 1 2 Innovation Close to Market Americas | Europe | Asia Co-create. Customize. Accelerate. Application labs and R&D centres enable faster response and tailored solutions. 3 Market Reach 80+ Countries Local relevance. Global strength. Deep market understanding supports customer alignment across regional needs and regulations. 4 Customer Partnerships 1,300+ Customers Worldwide Localized expertise. Agility. Trust. Serving global leaders and emerging innovators through flexible, long-term relationships. From Manufacturing to Global Partnerships Map not to scale. All data, information and maps are provided “as is” without warranty or any representation of accuracy, tim eliness or completeness.
Page 13
Specialty Ingredients Value – added Blends Performance Chemicals & Others Aroma Ingredients › TBHQ › BHA › Ascorbyl palmitate (ASP) › 200+ custom formulations, encompassing both traditional and natural solutions (forward-integrated antioxidant blends) › HQ derivatives products like Chloranil, MEHQ, HQEE, TBHQ, PDMB, CME, › CT derivative products like 4 TBC, Guethol, Veratrole, Guaiacol, 1, 2MDB › Vanillin, Ethyl Vanillin and Vanillin ex- clove (adorr ) › Pet Food › Livestock Nutrition › Food & Beverages › Fish Meal › Animal Feed Mills › Biodiesel › Aquaculture & Fishmeal › Rendering › Petrochemicals › Dyes & Pigments › Agrochemicals › Polymers › Pharmaceuticals › Acrylates › Electroplating › Printing Inks › Food & Beverages › Pharmaceutical › Incense sticks › Animal Feed › Flavors & Fragrance › Agrochemicals › Personal Care Key Products End User Industries Key Brands › These formulations are specifically tailored to meet the diverse needs of the industry › Aim to increase focus on high-value blends and additives FY26 Sales%*# 18% 58% 10% Straights 14% 13 # From continued operations Product Highlights
Page 14
14 # From continued operations TBHQ Highly effective antioxidant for protection against oxidative degradation. BHA Widely used antioxidant to preserve quality and extend shelf life. Ascorbyl Palmitate Fat-soluble antioxidant that helps maintain color, flavor and nutritional value Key Products Key End User Industries Livestock Nutrition Pet Food Food & Beverages Animal Feed Mills Biodiesel Aquaculture & Fishmeal Rendering Key Brands 3,812 4,576 4,111 3,744 3,143 FY22 FY23 FY24 FY25 FY26 Revenue Trend (Rs Mn) 1. a. Speciality Ingredients - Straights
Page 15
15 # From continued operations ▪ 200+ custom formulations, encompassing both traditional and natural solutions (forward- integrated antioxidant blends) ▪ Forward-integrated blends (TBHQ, BHA, BHT, ASP) effectively extend shelf life and prevent food/feed loss/wastage. Key Products Key End User Industries Bakery Products Pet Food Livestock Nutrition Animal Feed Mills Biodiesel Oils & Fats Rendering Key Brands Revenue Trend (Rs Mn) 4,168 5,103 7,474 8,612 9,973 FY22 FY23 FY24 FY25 FY26 1. b. Speciality Ingredients – Value Added Blends
Page 16
16 Vitafor Acquisition of Vitafor Invest NV 100% stake ▪ ▪ 100% stake acquired ▪ Cash consideration: €1 Mn ▪ Belgium-based platform ▪ ▪ Animal-feed ingredient manufacturer and trader ▪ Located near Port of Antwerp ▪ Established European network PRODUCT / APPLICATION FOCUS Animal feed ingredients Nutritional additives Specialty feed solutions Vinpai Strategic majority acquisition in Vinpai S.A. Majority stake PRODUCT / APPLICATION FOCUS Functional ingredients Emulsifier systems Processed-cheese solutions Strategic Impact Broader portfolio | New geographies | Cross-selling opportunities | Enhanced innovation capabilities TRANSACTION SNAPSHOT BUSINESS PROFILE ▪ ▪ Strengthens European & African reach ▪ Expands Pet Food & Feed exposure ▪ Creates Portfolio of cross- selling opportunities STRATEGIC VALUE ▪ ▪ ~83.82% Stake acquired in Dec -2025 ▪ Post open offer, company now holds 95.41% ▪ ▪ Ingredient-tech company ▪ Natural and functional systems ▪ Algae, plant, mineral & fibre-based solutions TRANSACTION SNAPSHOT BUSINESS PROFILE ▪ ▪ Deepens food-ingredient capabilities ▪ Adds functional blend portfolio ▪ Supports cross-technology innovation STRATEGIC VALUE Expanding Global Reach in Blends
Page 17
17 # From continued operations Revenue Trend (Rs Mn) Key Products Key End User Industries Food & Beverages Flavours & Fragrance Pharmaceuticals Animal Feed Incense Sticks Livestock NutritionAgrochemicals Vanillin Manufacture Methyl Vanillin under Vanesse serving multiple industries Ethyl Vanillin Manufacture Ethyl Vanillin under Evanil serving multiple industries Vanillin Ex-Clove Adorr vanillin range is manufactured inhouse ensuring consistent quality, reliable supply, and complete traceability. Key Brands 135 54 347 1,758 2,391 FY22 FY23 FY24 FY25 FY26 2. Aroma Chemicals
Page 18
18 # From continued operations HQ Derivatives Catechol Derivatives Key Products › Chloranil › MEHQ › HQEE › TBHQ › PDMB › CME › 4 TBC › Guethol › Veratrole › Guaiacol › 1, 2MDB Key End User Industries Petrochemicals Dyes & Pigments Acrylates Electroplating Agrochemicals Polymers Printing InksPharmaceuticals Key Brands 3. Performance Chemicals & Others
Page 19
19 # From continued operations 1. Speciality Ingredients (Straights + Blends + Vitafor + Vinpai) AMEA Region America Region ▪ Portfolio Expansion - Expand Xtendra®, NaSure®, and Enzentia® across food, functional ingredients, and animal nutrition ▪ Domestic Market Expansion – Strengthen poultry and scale aquaculture ▪ Export Growth - Expand internationally, especially in the Middle East. ▪ Growth & Market Positioning - Outpace industry growth through innovation and wider reach ▪ Speciality Solutions - Scale Xtendra®, NaSure®, Ezential® and Vinpai across food markets ▪ Animal Nutrition Growth – Expand performance nutrition, gut health and Vitafor solutions ▪ Biodiesel Expansion - Grow Brazil market share through scale and innovation. ▪ Market Development - Deepen customer partnerships and enter aquaculture and water treatment. 2. Aroma Chemicals Europe Region ▪ Expansion into high-potential markets ▪ Increased adoption of farm-level performance solutions ▪ Product Development with increased focus on ruminant nutrition ▪ Continued integration with global Animal Nutrition platform ▪ Deepened partnerships with key accounts ▪ Ongoing efforts to strengthen presence in core geographies ▪ Expansion with select high value customers across other regions ▪ Continued focus on quality, reliability and service excellence ▪ Optimizing supply chain and cost structures B r i n g i n g S c i e n c e t o E v e r y d a y L i f e Strategic Focus Areas across Segments 3. Performance Chemicals & Others ▪ Accelerate towards Speciality applications ▪ Expand presence in high- performance segments to reduce dependence on commodity price cycles ▪ Building on Diphenol platform and leveraging R&D capabilities
Page 20
20 • Diverse and experienced Board composition spanning technical and commercial expertise. • Regular, solutions-focused Board sessions to refine corporate policies and strategic priorities. • Strengthened risk-management practices aligned with the Company’s ESG objectives. • Progressed the FY2025–26 Global Reporting Initiative (GRI) assignment to strengthen sustainability reporting. • Completely renovated the Occupational Health Centre (OHC) to strengthen employee healthcare infrastructure. • Enhanced medical surveillance and wellness support for employees. • Successfully completed SEDEX audits, validating responsible workplace practices • Continued investment in workplace health, safety and inclusivity, particularly across manufacturing plants. • Transitioned from periodic monitoring to real-time environmental visibility through online installations, infrastructure upgrades • Undertook comprehensive thermal insulation program to minimize heat loss and optimize energy Environmental Social Governance ESG
Page 21
Ashish Dandekar Chairman & Managing Director › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing › Holds a BA in Economics and Management studies from Temple University, USA Amol Shah Independent Director › Managing Director of the MJ Group with over three decades of experience covering human healthcare, F&F compounds, plant protection, and water treatment chemicals › Holds an MBA from the University of Southern California and a Bachelor’s in Engineering from the University of Kent Nirmal Momaya Managing Director › Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy › He has been instrumental in providing strategic guidance & direction to the company on all significant business matters Mahabaleshwar Palekar Independent Director › Over three decades of experience with corporates in India and MNCs › Chemical engineer with a degree from the Institute of Chemical Technology (ICT) in Mumbai, India Arjun Dukane Executive Director- Technical › Chemical Engineer with over three decades of experience in the chemical industry › Has been associated with CFS for more than 15 years Joseph Conrad D’souza Independent Director › Erstwhile Member of Executive Management and Ex-Chief Investor Relations Officer of HDFC Ltd › Holds an M.com from Mumbai University and an MBA from South Gujarat University Harsha Raghavan Non-Executive Non-Independent Director › Managing Partner of Convergent Finance LLP and ex- founding MD & CEO of Fairbridge Capital (a Fairfax Company) › Holds an MBA & MSc in industrial engineering from Stanford University and a B.A from University of California, Berkeley Atul Pradhan* Independent Director › Former Head of Management Consulting at KPMG India, with extensive experience in strategy, business transformation, corporate governance and M&A. › Has led 100+ consulting engagements and served on CII and FICCI national committees › Served as Independent Director at Camlin Fine Sciences (2014–2021). Anagha Dandekar Non-Executive Non-Independent Director › President & co-founder of Hardware Renaissance, a manufacturer of handcrafted door hardware and accessories › Holds an MBA in Finance from the University of South Carolina, USA Abeezar Faizullabhoy Independent Director › Senior Partner at CMS Indus Law (Solicitors & Advocates) – Mumbai and ex-partner of J Sagar Associates › Holds Bachelor of Law from University of Mumbai and a Qualified Solicitor from Bombay incorporated law society › Was previously on Board of CFS for 13 years till 2019, His immense experience in the Corporate commercial, litigation, M&A Jens Van Nieuwenborgh Non-Executive Non-Independent Director › Board member of several companies across India and Europe, with extensive experience in business administration, finance, and operations › Holds an MBA from Harvard University and a Master’s in Science from Ghent University, Belgium. Radhika Dudhat Independent Director › Over three decades of experience with corporates in India and MNCs › Partner with Shardul Amarchand Mangaldas & Co. and has worked on a wide range of transactional, regulatory and legal risk management advisory › Holds degrees in Life Sciences and Law from the University of Bombay, with postgraduate studies at Cambridge and Harvard. 21 Board of Directors *Pradip Kanakia ceased as Independent Director upon completion of his tenure on October 18, 2026, while Atul Pradhan was appointed as Independent Director effective September 11, 2026.
Page 22
Ashish Dandekar Chairman & Managing Director › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research & development, product development, and marketing › Holds a BA in Economics and Management studies from Temple University, USA Nirmal Momaya Managing Director › Qualified Chartered Accountant with over three decades of experience in finance, taxation, audit, and management consultancy › He has been instrumental in providing strategic guidance & direction to the company on all significant business matters Arjun Dukane Executive Director- Technical › Chemical Engineer with over three decades of experience in the chemical industry › Has been associated with CFS for more than 15 years Santosh Parab President – Strategy and Global CFO › Over three decades of experience working auditing profession › Previously worked at renowned Indian accounting firm › Qualified Chartered Accountant with a Bachelor’s degree in commerce › Associated with CFS for more than 10 years Pankaj Pandey Chief Financial Officer › Over two decades of experience across finance & accounts › Qualified Chartered Accountant and cleared CISA › Previously worked with Transasia Bio Medicals, Sun Pharmaceutical Industries, KPMG, Glenmark Pharmaceuticals, Larsen & Toubro Nilesh Jadhav Chief Operating Officer › Chemical Engineer with around three decades of experience in the chemical industry including heading multilocational manufacturing sites › Previously worked at Balaji Amines, Deepak Fertilizers & Petrochemicals, Essar Refinery & Schenectady › Executive Management from IIM Bangalore and Piping Engineering from IIT Powai Eric Santos Vice President – Aroma Ingredients › Over two decades of industry experience, previously worked as a commercial director at Solvay S.A. › Holds a Bachelor’s degree in chemistry Jose Arturo Paulin Head – Mexico operations › Over two decades of experience in the feed market (premix, feed additives, pet food, and rendering) › Previously worked at Trouw Nutrition and Kemin Inc in Mexico › Qualifed agriculture engineer Jennifer Igou Head – USA operations › Over two decades of experience in food and pet-food space particularly in anti-oxidants & Hydrocolloids › Previously worked at Kemin Inc. USA & FMC › Holds a Bachelor's degree in Chemistry and Biology with an emphasis in Biomedicine 22 Senior Management Team
Page 23
Historical Financial Highlights
Page 24
Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) Net Debt to Equity (x) Net Debt to EBITDA (x) 10.8% 12.7% 7.0% Margin9.3% 24 0.64 0.65 0.65 0.51 0.52 FY22 FY23 FY24 FY25 FY26 3.1 3.2 5.8 2.1 5.1 FY22 FY23 FY24 FY25 FY26 14,121 16,816 2,000 FY22 FY23 14,131 FY24 16,287 641 FY25 17,233 635 FY26 16,131 16,928 17,868 1,528 2,131 1,790 2,160 1,069 -656 -586 -413 FY22 FY23 FY24 FY25 FY26 1,134 1,574 656 604 398 755 651 551 -315 FY22 FY23 -1,804 FY24 -2,232 FY25 FY26 -1,049 -1,581 235 Discontinued Operation Continued Operation 3.67% Historical Financial Highlights On Consolidated Basis
Page 25
Specialty Ingredients (Rs. In Mn) (Straights) Specialty Ingredients (Rs. In Mn) (Value added blends) Total Specialty Ingredients (Rs. In Mn) Aroma Ingredients (Rs. In Mn) Total Revenue Breakup (%)*Performance Chemicals & Others (Rs. In Mn)# 25On Consolidated Basis *Excluding Other Products 3,812 4,576 4,111 3,744 3,143 FY22 FY23 FY24 FY25 FY26 4,168 5,103 7,253 8,612 9,973 FY22 FY23 FY24 FY25 FY26 7,980 9,679 11,585 12,356 13,116 FY22 FY23 FY24 FY25 FY26 135 54 347 1,758 2,391 FY22 FY23 FY24 FY25 FY26 5,865 6,881 2,412 1,824 1,726 FY22 FY23 FY24 FY25 FY26 11% 14% 42% 41% 17% 11% 10% 30% 31% 52% 54% 58% 27% 28% 29% 23% 18% 1% FY22 0% FY23 3% FY24 FY25 FY26 13,980 16,614 13,691 15,938 17,233 # FY24, FY25 & FY26 figures excludes Diphenol CFS Europe and entire CFSWL discontinued operations Specialty Ingredients (Straights) Specialty Ingredients (Value Added Blends) Performance Chemicals Aroma Ingredients Operational Revenue Break-up #Performance Chemicals exclude intersegment revenue
Page 26
Thank You ! – shrikant.sangani@sgapl.net / shaily.p@sgapl.net http://www.sgapl.net/images/sgapl_logo.jpg – shrikant.sangani@sgapl.net / shaily.p@sgapl.net Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Shrikant Sangani / Shaily Patwa Email – shrikant.sangani@sgapl.net / shaily.p@sgapl.net Mobile No – 9619595686 / 9819494608 www.sgapl.net http://www.sgapl.net/images/sgapl_logo.jpg santosh.parab@camlinfs.com www.camlinfs.com santosh.parab@camlinfs.com www.camlinfs.com Camlin Fine Sciences Ltd. CIN – L74100MH1993PLCO75361 Santosh Parab - President – Strategy and Global CFO Email – santosh.parab@camlinfs.com www.camlinfs.com